CompletedPhase 2NCT03926936
FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study
Studying Endometrial stromal sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Frederic Amant
- Principal Investigator
- Frédéric Amant, MD PhD, MD,PHDUZ Leuven
- Intervention
- Fulvestrant(drug)
- Enrollment
- 17 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2019 – 2022
Study locations (14)
- CHU de Liege, Grivegnée, Liège, Belgium
- UZ Antwerp, Edegem, Belgium
- UZ Gent, Ghent, Belgium
- AZ Sint Maarten, Mechelen, Belgium
- Gynaecological Oncology, Radboudumc, Nijmegen, Gelderland, Netherlands
- medical Oncology, Maastricht University Medical Centrum+, Maastricht, Limburg, Netherlands
- Gynecological Oncology Centrum, Catharina Ziekenhuis, Eindhoven, North Brabant, Netherlands
- Amsterdam University Medical Centers (AMC), Amsterdam, North Holland, Netherlands
- The Netherlands Cancer Institute (NKI) - Antoni van Leuwenhoek Hospital (NKI-AvL), Amsterdam, North Holland, Netherlands
- Department of Obstetrics and Gynaecology, Leiden University Medical Center, Leiden, South Holland, Netherlands
- Gynaecological Oncology, Erasmus MC Cancer Institute, Rotterdam, South Holland, Netherlands
- Center for Medical Imaging, University Medical Centrum Groningen, Groningen, Netherlands
- Obstetrics and Gynaecology, University Medical Centrum Groningen, Groningen, Netherlands
- University Medical Centrum Utrecht, Utrecht, Netherlands
Collaborators
Kom Op Tegen Kanker · Research Foundation Flanders
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03926936 on ClinicalTrials.govOther trials for Endometrial stromal sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT03624244Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)Centre Leon Berard
- RECRUITINGNCT00005095Specimen and Data Study for Ovarian Cancer Early Detection and PreventionNorthwestern University